Copyright
©The Author(s) 2024.
World J Gastrointest Surg. Sep 27, 2024; 16(9): 2829-2841
Published online Sep 27, 2024. doi: 10.4240/wjgs.v16.i9.2829
Published online Sep 27, 2024. doi: 10.4240/wjgs.v16.i9.2829
Characteristics | Values |
Age (years), median (P25-P75) | 53 (47.5-58) |
< 60, n (%) | 49 (87.50) |
≥ 60, n (%) | 7 (12.50) |
Sex, n (%) | |
Male | 50 (89.29) |
Female | 6 (10.71) |
Viral infection, n (%) | |
Hepatitis B virus | 42 (75.00) |
Hepatitis C virus | 3 (5.36) |
Hepatitis B and C viruses | 11 (19.64) |
Prior cancer treatment modalities, n (%) | |
Untreated | 24 (42.86) |
Surgery | 6 (10.71) |
Ablation therapy | 3 (5.36) |
TACE | 23 (41.07) |
Line of immunotherapy, n (%) | |
First-line | 49 (87.5.0) |
Second-line | 5 (8.93) |
Third-line and beyond | 2 (3.57) |
Immunotherapy cycles | 4 (3-8.5) |
≤ 4 cycles | 29 (51.79) |
> 4 cycles | 27 (48.21) |
TACE sessions, median (P25-P75) | 1 (1-2) |
1 time, n (%) | 36 (64.29) |
2 times, n (%) | 13 (23.21) |
3 times or more, n (%) | 7 (12.50) |
Immunotherapy sequence, n (%) | |
Before | 21 (37.50) |
After | 35 (62.50) |
Concomitant targeted/immunotherapy, n (%) | |
No | 5 (8.93) |
Yes | 51 (91.07) |
Targeted/immunotherapy agents, n (%) | |
Lenvatinib | 36 (64.29) |
Apatinib | 3 (5.36) |
Bevacizumab | 3 (5.36) |
Regorafenib | 6 (10.71) |
Sorafenib | 3 (5.36) |
Targeted therapy duration (months), median (P25-P75) | 5 (3-9) |
Tumor maximum diameter (mm), median (P25-P75) | 65 (39-93.5) |
Tumor distribution, n (%) | |
Unilateral liver | 34 (60.71) |
Bilateral liver | 22 (39.29) |
Vascular invasion, n (%) | 21 (37.50) |
Extrahepatic metastasis, n (%) | 7 (12.50) |
BCLC staging, n (%) | |
A | 4 (7.14) |
B | 16 (28.57) |
C | 36 (64.29) |
Child-Pugh score, n (%) | |
A | 55 (98.21) |
B | 1 (1.79) |
ECOG performance status, n (%) | |
0 | 54 (96.43) |
1 | 2 (3.57) |
AFP (ng/mL), median (P25-P75) | 227.29 (38.7-9484.5) |
ALT (IU/L), median (P25-P75) | 38.9 (26.25-60.7) |
AST (IU/L), median (P25-P75) | 46 (34.25-76.2) |
Total bilirubin (µmol/L), median (P25-P75) | 16.4 (12.65-23.025) |
Number of patients | ORR (95%CI) | DCR (95%CI) | |
Total | 56 | 0.821 (0.717-0.923) | 0.875 (0.781-0.96) |
Age (years) | |||
< 60 | 49 | 0.816 (0.704-0.929) | 0.878 (0.782-0.973) |
≥ 60 | 7 | 0.857 (0.508-1.207) | 0.857 (0.508-1.207) |
Sex | |||
Male | 50 | 0.8 (0.685-0.915) | 0.86 (0.76-0.96) |
Female | 6 | 1 (1-1) | 1 (1-1) |
Viral infection | |||
Hepatitis B virus | 42 | 0.81 (0.686-0.933) | 0.833 (0.716-0.951) |
Hepatitis C virus | 3 | 0.667 (-0.768-2.101) | 1 (1-1) |
Hepatitis B and C viruses | 11 | 0.909 (0.707-1.112) | 1 (1-1) |
Prior cancer treatment modalities | |||
Untreated | 24 | 0.87 (0.721-1.018) | 0.913 (0.788-1.038) |
Surgery & Ablation therapy | 9 | 0.7 (0.354-1.046) | 0.8 (0.498-1.102) |
TACE | 23 | 0.87 (0.721-1.018) | 0.913 (0.788-1.038) |
Line of immunotherapy | |||
First-line | 49 | 0.857 (0.756-0.959) | 0.918 (0.839-0.998) |
Second-line and above | 7 | 0.571 (0.077-1.066) | 0.571 (0.077-1.066) |
Immunotherapy cycles | |||
≤ 4 cycles | 29 | 0.862 (0.729-0.996) | 0.897 (0.779-1.014) |
> 4 cycles | 27 | 0.778 (0.61-0.945) | 0.852 (0.709-0.995) |
Transarterial chemoembolization sessions, | |||
1 time | 36 | 0.889 (0.781-0.997) | 0.917 (0.822-1.012) |
2 times and above | 20 | 0.7 (0.48-0.92) | 0.8 (0.608-0.992) |
Immunotherapy sequence | |||
Before | 21 | 0.714 (0.504-0.925) | 0.762 (0.563-0.961) |
After | 35 | 0.886 (0.775-0.997) | 0.943 (0.862-1.024) |
Concomitant targeted/immunotherapy | |||
No | 5 | 0.8 (0.245-1.355) | 0.8 (0.245-1.355) |
Yes | 51 | 0.824 (0.715-0.932) | 0.882 (0.791-0.974) |
Targeted/immunotherapy agents | |||
Lenvatinib | 36 | 0.889 (0.781-0.997) | 0.917 (0.822-1.012) |
Apatinib, bevacizumab, regorafenib, or sorafenib | 15 | 0.667 (0.396-0.937) | 0.8 (0.571-1.029) |
Tumor distribution | |||
Unilateral liver | 34 | 0.941 (0.858-1.025) | 0.971 (0.911-1.03) |
Bilateral liver | 22 | 0.636 (0.418-0.855) | 0.727 (0.525-0.929) |
Vascular invasion | |||
Yes | 21 | 0.8 (0.661-0.939) | 0.857 (0.735-0.979) |
No | 35 | 0.857 (0.694-1.02) | 0.905 (0.768-1.042) |
Extrahepatic metastasis | |||
Yes | 7 | 0.816 (0.704-0.929) | 0.878 (0.782-0.973) |
No | 49 | 0.857 (0.508-1.207) | 0.857 (0.508-1.207) |
BCLC staging | |||
A or B | 20 | 0.9 (0.756-1.044) | 0.95 (0.845-1.055) |
C | 36 | 0.9 (0.756-1.044) | 0.95 (0.845-1.055) |
n (%) | |
Elevated ALT | |
Grade 0-2 | 51 (91.07) |
Grade ≥ 3 | 5 (8.93) |
Elevated AST | |
Grade 0-2 | 50 (89.29) |
Grade ≥ 3 | 6 (10.71) |
Elevated total bilirubin | |
Grade 0-2 | 54 (96.43) |
Grade ≥ 3 | 2 (3.57) |
Rash | |
Grade 0-2 | 54 (96.43) |
Grade ≥ 3 | 2 (3.57) |
Itching | |
Grade 0-2 | 56 (100.00) |
Grade ≥ 3 | 0 |
Vomiting | |
Grade 0-2 | 56 (100.00) |
Grade ≥ 3 | 0 |
Diarrhea | |
Grade 0-2 | 56 (100.00) |
Grade ≥ 3 | 0 |
Sensory abnormalities | |
Grade 0-2 | 56 (100.00) |
Grade ≥ 3 | 0 |
Thyroiditis | |
Grade 0-2 | 56 (100.00) |
Grade ≥ 3 | 0 |
Abdominal pain | |
Grade 0-2 | 56 (100.00) |
Grade ≥ 3 | 0 |
Gastric ulcer | |
Grade 0-2 | 56 (100.00) |
Grade ≥ 3 | 0 |
Bone marrow suppression | |
Grade 0-2 | 56 (100.00) |
Grade ≥ 3 | 0 |
- Citation: Tan BB, Fu Y, Shao MH, Chen HL, Liu P, Fan C, Zhang H. Combined transarterial chemoembolization and tislelizumab for patients with unresectable hepatocellular carcinoma. World J Gastrointest Surg 2024; 16(9): 2829-2841
- URL: https://www.wjgnet.com/1948-9366/full/v16/i9/2829.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v16.i9.2829